论文部分内容阅读
目的 评价美罗培南的安全性和有效性。方法 共入选 182例 ,其中试验组 90例 ,疗效评价 70例 ,不良反应评价 72例 ;对照组 92例 ,疗效评价 70例 ,不良反应评价 70例。给药方法为美罗培南 5 0 0mg/次 ,Q12h (必要时 1g ,Q12h) ,静脉点滴 30分钟 ;泰能 (亚胺培南 /西司他丁 ,5 0 0mg/5 0 0mg) ,5 0 0mg/次 ,Q 12h(必要时 1g ,Q12h) ,静脉点滴 30分钟 ,疗程均为 7- 14天。结果 两药临床有效率分别为 90 %与 87% ,细菌清除率分别为 86% (5 5 /64)和 86% (5 7/66) ,76% (93/12 3)的临床分离致病菌进行株致病菌产β 内酰胺酶阳性。不良反应发生率分别为 9.7% (7/72 )与 8.6% (6/70 )。以上结果经统计学处理无显著差异 (P >0 .0 5 )。结论 美罗培南治疗细菌性感染 (包括酶菌感染 )安全有效。
Objective To evaluate the safety and effectiveness of Meropenem. Methods A total of 182 cases were enrolled in the study, including 90 cases in trial group, 70 cases in efficacy evaluation, 72 cases in adverse reaction evaluation, 92 cases in control group, 70 cases in efficacy evaluation and 70 cases in adverse reaction evaluation. The administration method was meropenem 500mg / time, Q12h (1g, Q12h if necessary), intravenous drip for 30 minutes; tainen (imipenem / cilastatin, 500mg / 500mg) 0mg / time, Q12h (if necessary, 1g, Q12h), intravenous drip 30 minutes, treatment are 7-14 days. Results The clinical efficacies of the two drugs were 90% and 87%, respectively. The bacterial clearance rates were 86% (5/64) and 86% (57/66), respectively, and 76% (93/123) Strain strains of bacteria produce β-lactamase-positive. The incidence of adverse reactions were 9.7% (7/72) and 8.6% (6/70), respectively. The above results by the statistical analysis showed no significant difference (P> 0.05). Conclusion Meropenem is safe and effective in the treatment of bacterial infections (including bacterial infections).